Test Catalog

Test ID: NGAMT    
Next-Generation Sequencing Acute Myeloid Leukemia, Therapeutic Gene Mutation Panel (FLT3, IDH1, IDH2, TP53)

Useful For Suggests clinical disorders or settings where the test may be helpful

Evaluation of acute myeloid leukemia (AML) using a focused 4-gene panel at the time of diagnosis, or possibly relapsed or refractory disease, to help determine optimal (eg, targeted) therapeutic approaches

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test includes next-generation sequencing to evaluate for the following 4 genes: FLT3, IDH1, IDH2, and TP53.

Highlights

Next-generation sequencing detection of somatic gene mutations, including type, pattern, and distribution, has diagnostic, prognostic, and potential therapeutic implications for patients with hematologic cancers, such as acute myeloid leukemia (AML).

 

This test identifies targets for more accurate therapeutic management of AML.

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

See Targeted Genes Interrogated by Next-Generation Sequencing, Acute Myeloid Leukemia, Therapeutic, 4-Gene Panel in Special Instructions for a list of the genes and exons targeted by this test.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Somatic Mutation Detection by Next-Generation Sequencing (NGS)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

AML 4 Gene Panel, Therapeutic

Aliases Lists additional common names for a test, as an aid in searching

FLT3
IDH1
IDH2
Next gen sequencing of leukemia (AML)
Next Gen Sequencing Test
NGS cancer panel, hematologic
NGS hematologic malignancies
Somatic mutation detection by next generation sequencing (NGS), hematologic
TP53
Enasidenib therapy
Midostaurin therapy